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Abstract 
Background: Over the years, a number of distinct treatments have been adopted for 
the management of the motor symptoms of Parkinson’s disease (PD), including phar-
macologic therapies and deep brain stimulation (DBS). Efficacy is most often evaluated 
by subjective assessments, which are prone to error and dependent on the experience 
of the examiner. Our goal was to identify an objective means of assessing response to 
therapy.
Methods: In this study, we employed objective analyses in order to visualize and 
identify differences between three groups: healthy control (N = 10), subjects with 
PD treated with DBS (N = 12), and subjects with PD treated with levodopa (N = 16). 
Subjects were assessed during execution of three dynamic tasks (finger taps, finger to 
nose, supination and pronation) and a static task (extended arm with no active move-
ment). Measurements were acquired with two pairs of inertial and electromyographic 
sensors. Feature extraction was applied to estimate the relevant information from the 
data after which the high-dimensional feature space was reduced to a two-dimen-
sional space using the nonlinear Sammon’s map. Non-parametric analysis of variance 
was employed for the verification of relevant statistical differences among the groups 
(p < 0.05). In addition, K-fold cross-validation for discriminant analysis based on Gauss-
ian Finite Mixture Modeling was employed for data classification.
Results: The results showed visual and statistical differences for all groups and condi-
tions (i.e., static and dynamic tasks). The employed methods were successful for the 
discrimination of the groups. Classification accuracy was 81 ± 6% (mean ± standard 
deviation) and 71 ± 8%, for training and test groups respectively.
Conclusions: This research showed the discrimination between healthy and diseased 
groups conditions. The methods were also able to discriminate individuals with PD 
treated with DBS and levodopa. These methods enable objective characterization and 
visualization of features extracted from inertial and electromyographic sensors for dif-
ferent groups.
Open Access
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and 
indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdo-
main/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
RESEARCH
Machado et al. BioMed Eng OnLine  (2016) 15:169 
DOI 10.1186/s12938-016-0290-y BioMedical Engineering
OnLine
*Correspondence:   
alessandrorpmachado@
yahoo.com.br 
1 Postgraduate Program 
in Electrical and Biomedical 
Engineering, Faculty 
of Electrical Engineering, 
Centre for Innovation 
and Technology Assessment 
in Health (NIATS), Federal 
University of Uberlândia, 
Uberlândia, Brazil
Full list of author information 
is available at the end of the 
article
Page 2 of 22Machado et al. BioMed Eng OnLine  (2016) 15:169 
Keywords: Parkinson’s disease, Deep brain stimulation, Levodopa, Inertial sensors, 
Electromyography, Discriminant analysis
Background
Parkinson’s disease (PD) is a neurodegenerative disorder with progressive motor symp-
toms [1]. PD affects approximately 3% of the population over 65 years old [2] and is asso-
ciated with a severe loss in function of dopaminergic neurons within the substantia nigra 
pars compacta [3]. The primary symptoms of PD are tremors (oscillatory movements), 
bradykinesia (slow movement) and rigidity (increased muscular tone) [3–9]. PD can 
have significant negative impacts in several aspects of patients’ quality of life, including 
those associated with physical and social functioning, such as affecting patient’s ability 
to drink, eat and write [10–12].
There is a growing consensus that states that PD can manifest with different patterns 
[13]. Distinct subtypes manifest different symptom patterns, such as tremor dominant 
(TD) type and postural instability and gait difficult (PIGD) type (bradykinesia and rigid-
ity) [13, 14]. These subtypes are associated with different patterns of onset and rate of 
disease progression [15, 16]. Moreover, different PD subtypes have been linked to differ-
ent genetic patterns [14].
Ensuring a correct diagnosis is critical for prognostic and therapeutic reasons and also 
for clinical, epidemiological, and pharmacological studies [17]. Despite all the advances 
obtained in neuroimaging and genetics, the diagnosis of PD remains primarily clinical 
[17]. Severity of disease is most often evaluated with the subjective Unified Parkinson’s 
Disease Rating Scale (UPDRS) [18], which is composed of four parts: Part I (non-motor 
experiences of daily living), Part II (motor experiences of daily living), Part III (motor 
examination) and Part IV (motor complications). There are a number of alternative rat-
ing scales that are used for the evaluation of motor impairment and disability in patients 
with PD, but these scales have not been evaluated for validity and reliability [19]. Due 
to the subjective nature of these assessments and the need for improving the diagnosis 
and treatment efficacy, studies must be performed to provide feedback for neurologists 
during clinical evaluation of patients, reducing the time and effort required to achieve 
optimal outcomes and improving the treatment.
Regarding available treatments for PD, the drug levodopa is the gold standard [20]. 
Since the discovery that dopamine loss is associated with PD, this medication is recog-
nized as the most effective drug for PD treatment [1, 21]. However, long-term use of the 
medication leads to a levodopa-induced decrease in the efficacy of motor benefits and 
an increase in the incidence of adverse effects, which can contribute to worsening qual-
ity of life [20, 22, 23]. Invasive treatments, such as ablative surgeries and deep brain stim-
ulation (DBS) are also used for PD treatment, although ablative methods are now largely 
reserved for patients with contraindications to implantable hardware and in patients 
who live in countries with limited economic resources [24].
The use of DBS has been shown to improve motor symptoms in patients with 
advanced stages of PD that are responsive to traditional medical treatment [23]. DBS 
was approved by the US Food and Drug Administration to treat PD motor symptoms 
in 2002 [25]. Hyperactivity of the subthalamic nucleus and globus pallidus internus is 
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thought to underlie the pathophysiological mechanism of PD, making these basal gan-
glia regions the most commonly targeted sites for DBS [25]. DBS is applied in patients 
only if the symptomatic benefits are greater than the possible surgical risks and if DBS 
is likely to reduce overall symptomatology more effectively than drug therapy alone [12]. 
When optimized, DBS typically lessens motor symptoms, such as limb rigidity, akinesia, 
tremor and bradykinesia [23]. Regarding neuropsychological measurements after DBS 
surgery, some studies found decrease in cognitive functions [26] due to the development 
of apathy in some subjects [27].
A number of studies have compared outcomes between DBS and best medical man-
agement [12, 22, 23, 27–33]. Most of current studies employ subjective scales to measure 
the differences in the methods of treatment. The review of Xie et al. [23] evaluated dif-
ferences between DBS and medication treated groups, finding that individuals treated 
with DBS fared better than patients treated with medications with respect to motor 
complications as assessed by the UPDRS. However, the authors stated that due to the 
small number of studies, results must be prudently evaluated. Deuschl et al. [22] evalu-
ated 156 patients under 75 years old with advanced Parkinson’s disease and severe motor 
symptoms. They found that, according to subjective scales, DBS provided better out-
comes in social and motor results. It was also emphasized that the group that received 
neurostimulation is more susceptible to serious adverse effects, including fatal cerebral 
hemorrhage. De Gaspari et al. [33] also evaluated patients with medication and patients 
with DBS. It was found that both groups revealed significant improvements in the motor 
function. However, regarding neuropsychiatric scales, DBS seemed to be associated with 
significant worsening, resulting in long term behavioral problems for some patients.
Despite numerous studies comparing outcomes across groups, we could not iden-
tify in our literature review the systematic use of an objective method for comparing 
and visualizing the possible differences of individuals submitted to distinct treatment 
approaches. Furthermore, most studies do not contrast the motor behavior of healthy 
subjects with that of PD patients submitted to different treatments. As it is known that 
subjects with DBS show improvements in motor behavior when compared with subjects 
treated with medication [22, 23], an automatic classifier could theoretically be developed 
to compare these groups and show whether patients treated with DBS objectively dem-
onstrate the expected improvements. Furthermore, an objective discrimination between 
healthy subjects and PD patients treated with medication could provide us with param-
eters that may be related to the efficacy of the treatment, making it possible to improve 
medical management of PD [22].
In order to capture patterns of movements and objectively be able to analyze PD motor 
behaviors, wearable devices with built-in sensors are presented in several studies [2, 4, 5, 
34–37]. Most of the devices consist of wearable systems containing inertial sensors, such 
as gyroscopes and accelerometers and others use electromyographic sensors in order to 
collect electrical activity from the muscles of the affected limb.
This research describes the use of a system composed of a customized glove with built-
in inertial sensors (accelerometer, gyroscope and magnetometer) and electromyographic 
sensors, used for the characterization of wrist motor symptoms in three groups of sub-
jects. The first one is composed of PD patients treated with DBS, the second is composed 
of PD patients treated with levodopa and the third is composed of healthy subjects, with 
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no movement disorders. Each subject performed a set of static and dynamic tasks rou-
tinely employed by the neurologist during clinical evaluation. The aim of this study is to 
introduce a method for automatic classification between these groups, which can benefit 
our objective understanding of various treatments and improve patient management.
Methods
Characterization of the experimental group
This study was conducted in the Federal University of Uberlândia (UFU), Uberlândia, 
Brazil, and at the University of California, Los Angeles (UCLA), USA. Both institu-
tions provided ethical approval for the experimental procedures (UCLA IRB 14-001491; 
CAAE 07075413.6.0000.5152).
In total, 38 subjects participated in this study. These subjects were classified as neu-
rologically healthy individuals (SH  =  10), individuals with PD treated with levodopa 
(SPD = 16), and individuals with PD treated with DBS (SDBS = 12).
The inclusion criteria for the SPD group were the existence of PD motor complications, 
treatment with levodopa and absence of DBS implant. For the SH group, the inclusion 
criteria were the absence of movement disorder or any other neurological condition. The 
inclusion criteria for the SDBS group were the use of DBS for the treatment of PD motor 
complications.
Individuals of the experimental group SDBS (11 men and 1 woman aged between 59 
and 76 years old) were recruited at UCLA, whereas individuals of the SH group (3 men 
and 7 women aged between 23 and 64 years old) and SPD group (6 men and 10 women 
aged between 47 and 92 years old) were recruited at UFU.
Device for detecting and recording voluntary movement and tremor of the wrist
A customized glove was designed (National Industrial Property Institute, Brazil—INPI. 
Patent number: BR 10 2014 023282 6) including two sets of inertial sensors (Sensor 1 
and Sensor 2) (Fig.  1) and two pairs of disposable electromyographic (EMG) sensors 
(EMG 1 and EMG 2, in Fig.  2) (diameter of 36  mm, Ag/AgCl—Meditrace 200, Tyco/
Kendall, USA) that are placed on the limb of the individual. Each set of inertial sen-
sor (L3GD20H and LSM303D, STMicroelectronics, Switzerland) is composed of three 
axial accelerometers (minimum sensitivity of ±2 g), gyroscopes (minimum sensitivity of 
Fig. 1 Positioning of inertial sensors. Inertial sensors embedded in the custom-made glove for tremor meas-
urement. The unit 1 is positioned on the hand, whereas the unit 2 is positioned on the forearm
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±245°/s) and magnetometers (minimum sensitivity of ±2 gauss). The approximate mass 
of the composite sensor is less than 1 g. The glove was designed with neoprene, a very 
soft and comfortable material. Due to the softness of the glove, the subjects did not feel 
any discomfort during the procedures. The sensors could be removed from the glove for 
sterilization.
EMG signals were conditioned and low-pass filtered by specific hardware (EMG Sys-
tem do Brasil, Brazil) to identify the signal envelope. The system was battery powered for 
isolation purposes.
The signals were digitized at 50 Hz, by using a microcontroller (Atmel SAM3X8E ARM 
Cortex-M3). The resolution of the analog to digital converter was 12 bits. Data were sent 
to a laptop by means of serial communication. The control and real time visualization of 
data acquisition was performed by customized software (TREMSEN—Precise Tremor 
Sensing Technology) developed in C# (Microsoft). The software was configured to han-
dle data from up to four sets of inertial sensors (although only two sets were used in this 
study), two bipolar channels of EMG signals, and external pulses for synchronization 
and data annotation purposes (e.g., marking the beginning and end of tasks).
Data were saved in text format to be imported and processed in MatLab (MathWorks, 
USA).
Definition of experimental tasks
Each participant executed the basic sequence of four tasks depicted in Fig. 3 five times. 
At least 30 s was allowed for rest after the end of the execution of each sequence (from 
tasks 1 to 4).
The four tasks performed by the volunteers were finger taps (Task 1—T1), finger 
to nose (Task 2—T2), supination and pronation (Task 3—T3), and rest (i.e., extended 
arm with no voluntary movement, Task 4—T4). Each task was performed for 10  s in 
Fig. 2 Positioning of electromyographic sensors. EMG electrode positioned at the flexor muscles of the hand 
and at the extensor muscles of the hand. The reference electrodes are placed on the hand
Fig. 3 Experimental tasks. Basic sequence of executed tasks
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sequence. In order to annotate the sequence of tasks, an external pulse was generated by 
pressing a pushbutton every time the subject changed the movement.
Before the beginning of the data collection with the patients we applied the so-called 
tremor glove standard operating procedures (TGSOP), which is an optimized pro-
tocol that involves the glove and EMG sensor positioning, and also software settings. 
It describes exactly what was performed before, during and after data collection. The 
TGSOP procedure is given below.
 1. Setting up the glove system
a. Plug machine USB cable into laptop/computer;
b. Plug the external pulse generator into the External Pulse A port;
c. Plug the EMG amplifier battery into the VCC port;
d. Plug in the EMG electrodes:
i.    EMG 1—Electrodes are on wrist extensor muscles:
1. Ask the patient to extend the wrist up in order to find the contracted mus-
cles near lateral elbow;
ii. EMG 2—Electrodes are on wrist flexor muscles:
1. Ask the patient to flex the wrist down in order to find the contracted mus-
cles near medial elbow;
iii.  Place both EMG ground electrodes near little digit, just distal to ulnar wrist 
(hypothenar compartment).
 2. Configure the TREMSEN software (data collection software)
a. Check settings, click start and make sure that the motions are not oversaturated 
on recording window;
b. Write down the current settings and configurations on protocol form;
c. Inertial sensor sensitivity settings:
i.   Accelerometer: ±6 g;
ii.  Gyroscope: ±2000°/s;
iii. Magnetometer: ±2 gauss;
 3. Put glove on the tested hand—note the hand tested
 4. Check with neurologist which hand has worse tremors
 5. Start acquisition, have patient extend arm and rotate their hand to check for over-
saturation
 6. Have the patient do the following tasks for 10 s each
d. Finger taps;
e. Hand movements (finger to nose);
f. Rotation of the hands (pronation and supination);
g. Holding the arm in full extension and with no voluntary movement;
h. Make sure to press external pulse when switching movements;
 7. Tell patient to rest for 30 s
 8. Repeat step 6 and 7 for more four times
 9. Stop acquisition
 10. Save file as patient #
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i. Check if files are saved before closing the software;
j. It is also advised to keep a separate file of notes of any incidents that may occur 
during the recording, as well as relevant patient information.
Data analysis
The flowchart in Fig. 4 summarizes the main steps for data analysis. The signals were 
sampled at 50 Hz.
The resultant component (step 1 in Fig. 4) of each signal was estimated as in (1), in 
which X, Y and Z are the individual coordinates measured by the employed sensors.
The resultant component was then filtered by means of a bandpass Butterworth filter 
of order 4, lower cutoff frequency of 0.5 Hz and upper cutoff frequency of 25 Hz (step 
2 in Fig. 4). A zero-phase forward and reverse digital IIR filtering was applied to avoid 
phase distortions. The main aim of this step was to eliminate the influence of undesired 
low frequency components over the collected signals (e.g., Gravity, Earth’s magnetic 
field).
In order to reduce the influence of linear and non-linear trends over the preprocessed 
signal, it was subtracted from its mean and also from 20th order polynomial capable 
of capturing nonlinear trends in the data (step 3 in Fig.  4). The main aim of this step 
is to guarantee that the data oscillates evenly around zero. As there is the execution of 
many types of tasks in a single trial the inertial sensors are subjected to distinct condi-
tions (e.g., effect of gravity and Earth’s magnetic field), thus the resulting trend is not 
linear and it cannot be removed from the time-series by subtracting it from its mean. 
A usual method in signal processing to deal with such a condition is the application of 
polynomials for non-linear trend detection and removal [38]. The Hilbert transform of 
(1)R =
√
X2 + Y 2 + Z2
Fig. 4 Signal processing steps. Flowchart depicting the main steps for signal processing
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the preprocessed signal was employed for the estimate of the instantaneous amplitude 
and frequency (step 4 in Fig. 4), as described in previous work [39].
As described in [40] for an arbitrary time series, X(t), the Hilbert Transform, Y(t), is 
obtained from (2),
where P is the Cauchy principal value defined by (3),
where R may be seen as an auxiliary variable responsible for transforming the indefinite 
integral into a definite one. With this definition, X(t) and Y(t) form the analytical signal, 
Z(t), as (4)
in which (5) is the instantaneous amplitude
and (6) the instantaneous phase
The instantaneous frequency was defined in [41] as (7)
In order to identify the beginning and the end of each task, a visual inspection of the 
signal was performed so that the annotated periods could be used for feature extraction 
within the regions of interest (step 5 in Fig. 4).
Figure 5 illustrates typical waveforms of resultant components for the inertial and elec-
tromyographic sensors. The periods of the sequence of executed tasks (T1, T2, T3, T4) 
are delimited by rectangular windows, indicating the beginning and end of each task.
Feature extraction was performed over the Filtered signal (FS), the Instantaneous 
Amplitude (IA) and the Instantaneous Frequency (IF), as indicated in the step 6 in Fig. 4. 
The following features, which are fully described in Table 1 of [42], were estimated:
Amplitude features
MAV  Mean absolute value;
RMS  Root mean squared deviation;
PEAK  Global maximum;
MAVSDN  Mean of the absolute values of the second differences of the normalized 
signal;
(2)Y (t)
1
pi
P
∞∫
−∞
X(t ′)
t − t ′
dt ′
(3)P
∞∫
−∞
X(t ′)
t − t ′
dt ′ = lim
R→∞
R∫
−R
X(t ′)
t − t ′
dt ′
(4)Z(t) = X(t)+ iY (t) = a(t)ejθ(t)
(5)a(t) = [X2(t)+ Y 2]
1
2
(6)θ(t) = arctan
(
Y (t)
X(t)
)
(7)ω(t) =
(
dθ(t)
dt
)
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MAVSD  Mean of the absolute values of the second differences;
MAVFDN  Mean of the absolute values of the first differences of the normalized 
signal;
MAVFD  Mean of the absolute values of the first differences of the signal
Variability features
INTERQ_RANGE  Interquartile range of the signal;
RANGE  Difference between the maximum and minimum values of a 
signal;
STD  Standard deviation;
VAR  Variance
Entropy
Approximate entropy—it measures the number of specific ways in which a system may 
be arranged, often taken to be a measure of disorder.
For each method (i.e., FS, IA and IF), a feature matrix was created containing the fea-
tures extracted from all sensors. In addition, it was analyzed the combination of features 
estimated from each method: FS–IA, FS–IF, IA–IF, FS–IA–IF. The aim was to identify 
which combination could provide us with the best discrimination results.
In order to reduce the dimensionality of the feature space to a two-dimensional space, 
the Sammon’s mapping method was used (step 7 in Fig.  4). The Sammon’s algorithm 
maps a high-dimensional space and converts it to a space of lower dimensionality, try-
ing to preserve the structure of inter-point distances in high-dimensional space in the 
lower-dimension projection [43]. The selection of Sammon’s map is based on the rela-
tive success of this method for dealing with nonlinearities inherent to our data type 
[44].
Fig. 5 A typical example of preprocessed data. Typical results of the application of the windowing and 
filtering steps. The distinct tasks (T1, T2, T3 and T4) are separated by the pulses. Information regarding sensors 
1 and 2 are presented in accordance to their physical location shown in Figs. 1 and 2. The external pulses 
are indicated by vertical lines between tasks. In periods between sequence of tasks the subject was free to 
execute any desired movement or to relax, thus, they are not considered in the data analysis
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Data projections were carried out for each specific task and then a scatter plot of the 
obtained projection was generated (step 8 in Fig. 4), so that possible differences among 
the studied groups could be visualized.
The analysis of the lower dimensional data was performed by means of two distinct 
strategies: (i) the use of statistical analysis; (ii) the evaluation of classification results.
Statistical analysis
For the statistical evaluation of the data (step 9 in Fig. 4), the non-parametric analysis 
of variance method (NPMANOVA—non-parametric MANOVA) was applied. This is 
because the bivariate normality presupposition was not satisfied for any of the tasks. The 
bivariate normality presupposition was verified by means of the Mardia test [45]. But, 
at the significance level of 5%, the bivariate normality was not successful with any of the 
tasks.
The NPMANOVA, also known as PERMANOVA (permutational multivariate analy-
sis of variance) is widely used for ecological data. The test consists in comparing meas-
urements of distances between observed pairs within the same group versus distances 
in different groups, so it is a nonparametric test that compares distance between two 
or more groups by means of distance measurements [46]. In the NPMANOVA analysis 
it was used the Euclidean distance, considering 10,000 permutations. This analysis was 
performed in the software PAST (PAleontological STatistics) [47] with a confidence level 
of 95%. The Bonferroni’s correction was applied. It was performed by multiplying the p 
values by the number of paired comparisons of the values obtained from each feature 
matrix (FS, IA, IF, FS–IA, FS–IF, IA–IF and FS–IA–IF).
Classification analysis
In addition to the statistical analysis, K-fold cross-validation for discriminant analysis 
based on Gaussian finite mixture modeling [48] was employed for data classification 
(step 10 in Fig. 4). For this the toolbox mclust (available in R Project for Statistical Com-
puting [49]) [50] was used. The eigenvalue decomposition discriminant analysis (EDDA) 
[48] model and a K of 10 were employed. The low dimensional data set (2D) was used as 
input for the model.
The training and test sets were created randomly, by selecting data from five partici-
pants for each group (SH, SPD, SDBS), and without repetition (i.e., data from individuals of 
the training set were not used in the test set) in order to validate the classifier and avoid 
overfitting. In total, 1000 pairs of training and test sets were created.
The accuracy of the classifier was measured by means of the normalized success rate 
(0–1), which is the number of correctly classified patterns of a class over the total num-
ber of patterns of this class.
Results
Visualization and statistical results of projected data
Figure 6 depicts an example of data projection and dimensionality reduction obtained by 
the combination of features extracted from the FS and IA (FS-IA) methods. In the figure, 
it is possible to observe the separation between groups. Results for each task are shown 
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in A (Task 1), B (Task 2), C (Task 3) and D (Task 4). In the figure the triangles represent 
SDBS, circles represent SH and asterisks represent SPD.
Visually there was a clear separation among groups for all tasks and feature combina-
tions. For all the tasks and methods, the p value with Bonferroni’s correction was lower 
than 0.05. This statistically confirmed the discrimination between the three groups.
Classification results of projected data
Table 1 presents the success rate (normalized between 0 and 1) for the data (i.e., classifi-
cation data set) employed for training the classifier, whereas Table 2 shows the results of 
new data (i.e., test data set) presented to the trained classifier.
Fig. 6 Visualization of projected data onto a lower dimensional space. Separation of groups by the use of the 
Sammon’s projection method. The visualizations are scatter plots representing dimensionless scores of the 
nonlinear projection of high-dimensional feature vectors (FS-IA) onto the first (x axis) against the second (y 
axis) estimated components. Triangles represent SDBS, circles SH and asterisks SPD. a represents Task 1, b Task 
2, c Task 3 and d Task 4
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Tasks
Task 2 (finger to nose) had the highest success rate (overall mean 0.80 and 0.72, respec-
tively for the classification and test sets). Task 3 (supination and pronation) presented 
the worst overall success rate (0.71, for the classification set) while Task 4 (rest) showed 
the worst overall success rate (0.66) for the test set. Task 2 yielded the lowest overall 
mean standard deviation for the classification and test sets, respectively, 0.04 and 0.04. 
The largest overall mean standard deviation was for Task 4 (0.13 and 0.12, for classifica-
tion and test sets, respectively).
Preprocessing methods
Considering the methods, the preprocessing method FS–IF was the one which yielded 
the highest success rates (overall mean respectively 0.81 and 0.71 for the classification 
and test sets), and the methods FS and IF showed the worst success rates for classifica-
tion sets (0.74) and FS showed the worst success rate for test sets (0.63). Also, it could 
be observed that for Tasks 1, 2 and 3, the best method was FS–IF for both classification 
(0.80, 0.86 and 0.83, respectively) and test (0.71, 0.79 and 0.74, respectively) sets, and 
for Task 4 the best method for classification was IA-IF and FS-IA-IF (0.76) and the best 
method for test was IF (0.63) sets. The highest overall standard deviation was obtained 
from the method IF, for both classification and test sets (0.10 and 12 respectively).
Discrimination among groups
SH showed the highest success rates for the classification set for FS–IF (0.89) and the 
highest success rates for the test set for IF and FS–IF (0.82). SPD showed the highest suc-
cess rates for the classification for IA, FS-IA and FS–IF (0.76) and the highest success 
rates for the test set for FS–IF (0.64). Finally, SDBS showed the highest success rate for the 
classification and test sets for FS–IF (0.78 and 0.68, respectively).
SDBS group showed the worst mean success rate for tasks 1, 2 and 4 (0.72, 0.77 and 
0.60, respectively) compared to SH (0.85, 0.85 and 0.94, respectively) and SPD (0.74, 0.81 
and 0.69, respectively). Only for Task 3, SPD showed the lowest success rate compared to 
other groups (0.77—SH, 0.69—SPD and 0.79—SDBS).
Considering the mean values of all the methods and for each task in SH, Task 4 yielded 
the highest success rate for the classification and test sets (0.94 and 0.80, respectively) 
and Task 3 yielded the worst success rate for the classification and test sets (0.77 and 
0.69, respectively). For SPD, Task 2 yielded the highest success rate for the classification 
and test sets (0.81 and 0.70, respectively) and Tasks 3 and 4 yielded the worst success 
rate for the classification set (0.69) and Task 4 the worst success rate for the test set 
(0.54). Finally, for SDBS, Task 3 yielded the highest success rate for the classification set 
(0.79) and Tasks 2 and 3 showed the highest success rates for the test sets (0.69) and 
Task 4 yielded the worst success rate for the classification and test sets (0.60 and 0.50, 
respectively).
Discussion
Consistent with the literature [12, 22, 23, 27–33] our results demonstrated differences 
between movement patterns for the three groups. We however introduce the possibility 
of visualizing and classifying the data obtained from subjects objectively, independent of 
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the experience of examiners and subjective rating scales. Based on our review, this is the 
first study in this direction.
From the proposed method for data analysis, several parameters could be extracted 
from individual’s data. Parameters regarding the tasks, preprocessing methods and sub-
jects provided important information regarding specific characteristics of groups of 
individuals and treatments.
Our results take in account the differentiation of PD treatments and a healthy control 
group without considering the subtypes of the disease. It is not known whether the exist-
ence of these subtypes of the disease have generated any influence over our results, since 
tremor, bradykinesia and rigidity present different movement patterns. The variability 
found in some methods may be due to this factor. Also, there is the possibility of differ-
ent behaviors in the execution of the tasks provided by the subtypes. A further study, 
with the use of our system and protocol in new groups of participants, separated by PD 
subtypes, could address this issue.
The relevance of the tasks
From a methodological perspective, the tasks performed in this study are well estab-
lished, described in the UPDRS [18] and used in clinical evaluation. Several studies 
evaluated finger taps (Task 1) [51–55], finger to nose task (Task 2) [51], pronation and 
supination (Task 3) [56], and postural tremor of the hands (Task 4) [57]. Thus, results 
from our study came from real procedures widely used in neurological assessments.
According to the visualization obtained from the Sammons mapping technique, the 
groups could be discriminated while executing the distinct experimental tasks. These 
results confirm the discriminations already observed in subjective evaluations and, addi-
tionally, confirm that the executed tasks allow for the discrimination between groups 
and types of treatment. Further detailed studies will be required both within subjects 
and across conditions and with precise comparisons with clinical scales to further vali-
date this approach.
The classification results were presented in order to support the visual information 
provided by the Sammon’s map projection. The classification analysis allows for the eval-
uation of models for the groups, which are generated through the available experimental 
data. In order to analyze the generalization of the model, i.e., results based on data sets 
not used for the model estimate, we divided our data sets into classification and test sets. 
By taking into account this we were able to obtain the results shown in Tables  1 and 
2, from which it was possible to objectively understand differences among the groups, 
tasks and preprocessing methods.
The task that yielded the best success rate was Task 2 (finger to nose). For this task 
the overall mean success rate was of 0.80 and 0.72, for the classification and test sets, 
respectively. When compared to the other tasks, Task 2 is considerably more complex 
and with the largest movement extension, as it involves the coordination of the arm, 
forearm and shoulder. However, this motor complexity seems to generate data patterns 
that best characterize (i.e., yields less overlapping between groups) the studied groups as 
confirmed by the success rates shown in Tables 1 and 2.
Still, the relatively high success rates (above 0.75 and 0.61 for the classification and 
test sets, respectively) obtained for the other tasks indicate they cannot be neglected for 
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discrimination purposes. Future studies should consider the joint analysis of features 
extracted from distinct types of tasks, with the aim of improving success rates.
Although the four tasks demonstrated good results regarding group separation, other 
tasks, which are part of the clinical routine, can also be analyzed in the future.
The role of the preprocessing method
In this study, three preprocessing methods were employed. The first (FS) was based on 
the filtered signal, which yields data more correlated with the original data; the second 
(IA) takes into account changes in the amplitude of the signal; and the third (IF) captures 
changes in the signal frequency over time.
From our results, it is possible to conclude that the combination (i.e., joint analysis of 
features extracted from the methods FS and IF) was the one that yielded the best overall 
success rate. When considering Task 2 and FS–IF, we report a success rate of 0.86 and 
0.79 for the classification and test sets, respectively. The success of this method (when 
compared to the IA and its combinations) may be related to the considerably high over-
lap between amplitude components yielded by the execution of distinct tasks.
The overall evaluation of the success rates
A summary of the overall mean success rates and their standard deviation (estimated 
from Tables 1, 2) for the true positive predictions are given below:
  • SH (SH): 0.85 ± 0.05 and 0.75 ± 0.04 for classification and test sets, respectively;
  • SPD (SPD): 0.73 ± 0.05 and 0.60 ± 0.07 for classification and test sets, respectively;
  • SDBS (SDBS): 0.72 ± 0.06 and 0.63 ± 0.07 for classification and test sets, respectively.
From Tables 1 and 2 it is also possible to estimate the overall degree of overlapping 
between groups (and its standard deviation) as shown below:
  • SDBS (SPD): 0.19 ± 0.07 and 0.24 ± 0.09 for classification and test sets, respectively;
  • SPD (SDBS): 0.12 ± 0.03 and 0.20 ± 0.05 for classification and test sets, respectively;
  • SH (SPD): 0.11 ± 0.05 and 0.17 ± 0.05 for classification and test sets, respectively;
  • SPD (SH): 0.14 ± 0.04 and 0.20 ± 0.05 for classification and test sets, respectively;
  • SH (SDBS): 0.04 ± 0.02 and 0.07 ± 0.02 for classification and test sets, respectively;
  • SDBS (SH): 0.09 ± 0.03 and 0.12 ± 0.03 for classification and test sets, respectively.
SPD showed overlapping with the two other groups. This may be related to the vari-
ability of the results of the treatment (levodopa), which is time-dependent, and thus can 
yield a larger variability of motor patterns.
The inter-group variability was low (less than 0.07) suggesting similarities of motor 
patterns of individuals within the same group.
Potential and practical applications
The results found in this study can be employed in distinct contexts. The data visualiza-
tion shown in Fig.  6 and the boundaries for distinct groups (which is essentially cre-
ated by the classification method) could be considered as typical motor patterns for each 
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group, projected onto a low dimensional space. The main limitation of our study is the 
relatively low number of participants, however as this number increases the reliability 
of the model also increases, and then the better this model could represent the actual 
world, by taking into account the inherent variability of inertial and electromyographic 
data.
In many circumstances, the diagnosis of PD is not straightforward, thus the discrimi-
nation between healthy control and affected subjects is beneficial for both initial diagno-
sis and the management of disease progression.
In the worst scenario, when the disease cannot be managed by the use of medication, 
or when this medication interferes with the quality of life of patients, the current medical 
guidelines suggest consideration of surgical intervention. Regarding DBS, the consensus 
is to provide the surgery to PD patients when levodopa fails to provide consistent benefit 
and all other options have not been successful. Taking this information into account, 
Xie et al. [23] suggested that in order to evaluate the best moment for the DBS implant 
surgery, more studies should be performed. Furthermore, the expectation of improving 
the quality of life of patients treated with DBS has to be weighed against the risk of some 
serious complications related to surgery [22]. Adverse effects of DBS consist in hemor-
rhage resulting in permanent neurological deficit or death in 1.1%, infections, electrode 
migrations or misplacements, skin erosion, wire fractures and device malfunction. The 
rate of appearance of these complications are between 4.3 and 17.8% [23]. In general, 
DBS is a relatively safe approach, but not free from risks. By using the visualization tools 
such as that in Fig. 6 one could objectively monitor the progress of the disease, by com-
paring motor patterns of the patients with that of groups of people with PD. A more 
important point is that such a visualization of data points is able to show whether the 
patient is leaving the area of medication treated patients, and this could be an evidence 
of motor deterioration, which could be used in the decision of recommendation for DBS.
An innovative aspect of our research is certainly the inclusion of individuals with DBS 
implant. By doing this we were able to visualize motor patterns of these individuals, 
which has not been reported in the literature. The specific motor patterns of DBS users 
should be further studied and explained, by synchronizing information from the stimu-
lator, inertial, electromyographic and electrocorticographic signals.
Data from more patients treated with medication can be included in the database and 
thus, further studied. The use could be straightforward: when the subject is not classi-
fied in the expected group clinicians should verify whether the proposed treatment is 
as effective as it should be. In such a scenario, different management schemes could be 
pursued in order to optimize patient management and care.
Conclusions
In conclusion, the device and methods described in this study could potentially improve 
upon current management algorithms for patients with PD, potentially limiting the 
role of subjective methods and scales that are sensitive and therefore limited by human 
bias. The visualization provided by the Sammon’s map preserves the distance between 
groups, so that they could be clearly identified for all investigated tasks. The preprocess-
ing method based on the combination of filtered signals with their instantaneous ampli-
tude (FS–IF) was the one that provided the best success rates, being the most effective 
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in discriminating the three studied groups. The static task (Task 4) allowed for the best 
discrimination of healthy individuals. Task 2 (finger to nose) allowed for the best dis-
crimination of PD subjects and Task 3 (supination and pronation) showed the best dis-
crimination of DBS subjects.
Abbreviations
DBS: deep brain stimulation; PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale; EMG: 
electromyography.
Authors’ contributions
AR participated in the idealization of the study, performed data collection and participated in the draft of the paper. HC 
worked in the development of the hardware used in this study. AP participated in the idealization of the study and data 
collection. GL worked in the development of the hardware used in this study. FH contributed in data analysis and in the 
paper drafting. JA, GL worked in the development of the hardware used in this study. JM performed the statistical analy-
sis and participated in the discussion of the paper. NP participated in the idealization of the study, provided access to the 
neurology department from UCLA and participated in the paper drafting. YB provided access to the neurology depart-
ment from UCLA and participated in the paper drafting. LY participated in the idealization of the study and data collec-
tion. XZ participated in the idealization of the study and data collection. AO participated in the idealization of the study 
and data collection. JS participated in the idealization of the study and data collection. KN participated in the idealization 
of the study and paper drafting. AA participated in the idealization of the study and paper drafting. MF participated in 
the idealization of the study and paper drafting. AOA participated in the idealization of the study, development of the 
hardware and software employed for data collection, data analysis, and in the paper drafting.
Author details
1 Postgraduate Program in Electrical and Biomedical Engineering, Faculty of Electrical Engineering, Centre for Innovation 
and Technology Assessment in Health (NIATS), Federal University of Uberlândia, Uberlândia, Brazil. 2 Faculty of Math-
ematics, Federal University of Uberlândia, Uberlândia, Brazil. 3 Department of Neurosurgery, University of California, Los 
Angeles, USA. 4 Department of Neurology, University of California, Los Angeles, USA. 5 Neurology and Neurological Sci-
ences, Stanford University, Stanford, CA, USA. 6 Bioengineering and Biomechanics Laboratory, Federal University of Goiás, 
Goiânia, Brazil. 
Acknowledgements
The authors are grateful to Brazilian Government Agencies CAPES, CNPq, FAPEMIG and FAPEG for supporting the study. 
The authors also extend appreciation to the subjects who volunteered for this study. NP is supported in part by a NIBIB 
award (K23EB014326) as well as philanthropic support from the Casa Colina Centers for Rehabilitation.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The table with features extracted from the raw data used in this study are available upon request to the corresponding 
author.
Ethics approval and consent to participate
The study was approved by University of California, Los Angeles (UCLA Institutional Review Board—UCLA IRB 14-001491) 
and Federal University of Uberlandia (CAAE 07075413.6.0000.5152).
Funding
The following Brazilian governmental agencies supported the study providing financial resources for the system con-
struction and data collection in Brazil and in the United States: CAPES, CNPq, FAPEMIG and FAPEG.
NP is supported in part by a NIBIB award (K23EB014326) as well as philanthropic support from the Casa Colina Cent-
ers for Rehabilitation.
Received: 5 August 2016   Accepted: 26 November 2016
References
 1. Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levo-
dopa) clinical efficacy and safety. Neurology. 2016;86(14 Suppl 1):S13–24.
 2. Patel S, Lorincz K, Hughes R, Huggins N, Growdon J, Standaert D, Akay M, Dy J, Welsh M, Bonato P. Monitoring 
motor fluctuations in patients with Parkinson’s disease using wearable sensors. IEEE Trans Inf Technol Biomed. 
2009;13(6):864–73.
 3. Shah RS, Chang SY, Min HK, Cho ZH, Blaha CD, Lee KH. Deep brain stimulation: technology at the cutting edge. J 
Clin Neurol. 2010;6(4):167–82.
 4. Houde D, Otten B, Mehrkens JH, D’Angelo LT, Lueth TC. A novel glove monitoring system used to quantify neuro-
logical symptoms during deep-brain stimulation surgery. Sens J IEEE. 2013;13(9):3193–202.
Page 21 of 22Machado et al. BioMed Eng OnLine  (2016) 15:169 
 5. Rissanen SM, Kankaanpaa M, Tarvainen MP, Novak V, Novak P, Hu K, Manor B, Airaksinen O, Karjalainen PA. Analysis of 
EMG and acceleration signals for quantifying the effects of deep brain stimulation in Parkinson’s disease. IEEE Trans 
Biomed Eng. 2011;58(9):2545–53.
 6. Stacy M. Medical treatment of Parkinson disease. Neurol Clin. 2009;27(3):605–31.
 7. Giuffrida JP, Riley DE, Maddux BN, Heldman DA. Clinically deployable Kinesia technology for automated tremor 
assessment. Mov Disord. 2009;24(5):723–30.
 8. Jahanshahi M. Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over 
prepotent responses in Parkinson’s disease. Front Syst Neurosci. 2013;7:118.
 9. Patel S, Mancinelli C, Hughes R, Dalton A, Shih L, Bonato P. Optimizing deep brain stimulation settings using wear-
able sensing technology. In: 2009 NER ‘09 4th international IEEE/EMBS conference on neural engineering, April 29 
2009–May 2 2009. 2009. p. 6–9.
 10. Teskey WJE, Elhabiby M, El-Sheimy N. Inertial sensing to determine movement disorder motion present before and 
after treatment. Sensors. 2012;12(3):3512.
 11. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol 
Neurosurg Psychiatry. 2000;69(3):308–12.
 12. St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on 
balance and gait in PD. Neurology. 2010;75(14):1292–9.
 13. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499–504.
 14. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural insta-
bility/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison 
with the unified Parkinson’s disease rating scale. Mov Disord. 2013;28(5):668–70.
 15. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in 
Parkinson’s disease. Brain. 2009;132(Pt 11):2947–57.
 16. van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J. The identification of Parkinson’s disease 
subtypes using cluster analysis: a systematic review. Mov Disord. 2010;25(8):969–78.
 17. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: 
a systematic review and meta-analysis. Neurology. 2016;86(6):566–76.
 18. The Unified Parkinson’s Disease Rating Scale (UPDRS). Status and recommendations. Mov Disord. 2003;18(7):738–50.
 19. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76.
 20. Sharma A, Szeto K, Desilets AR. Efficacy and safety of deep brain stimulation as an adjunct to pharmacotherapy for 
the treatment of Parkinson disease. Ann Pharmacother. 2012;46(2):248–54.
 21. Muñoz P, Paris I, Segura-Aguilar J. Commentary: evaluation of models of Parkinson’s disease. Front Neurosci. 
2016;10:161.
 22. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eis-
ner W, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.
 23. Xie C-L, Shao B, Chen J, Zhou Y, Lin S-Y, Wang W-W. Effects of neurostimulation for advanced Parkinson’s disease 
patients on motor symptoms: a multiple-treatments meta-analysas of randomized controlled trials. Sci Rep. 
2016;6:25285.
 24. Machado A, Rezai AR, Kopell BH, Gross RE, Sharan AD, Benabid AL. Deep brain stimulation for Parkinson’s disease: 
surgical technique and perioperative management. Mov Disord. 2006;21(Suppl 14):S247–58.
 25. Chen XL, Xiong YY, Xu GL, Liu XF. Deep brain stimulation. Interv Neurol. 2012;1(3–4):200–12.
 26. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, Krause M, Tronnier V, Kloss M, Schnitzler A, et al. Neuropsy-
chological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre 
study. Lancet Neurol. 2008;7(7):605–14.
 27. Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, Pezzoli G. A 5-year prospective assessment of advanced 
Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 
2011;258(4):579–85.
 28. Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkin-
son’s disease. Mov Disord. 2007;22(6):757–65.
 29. Schupbach WM, Maltete D, Houeto JL, du Montcel ST, Mallet L, Welter ML, Gargiulo M, Behar C, Bonnet AM, 
Czernecki V, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology. 
2007;68(4):267–71.
 30. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, et al. Bilateral deep 
brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled 
trial. JAMA. 2009;301(1):63–73.
 31. Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, et al. Deep brain stimu-
lation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): 
a randomised, open-label trial. Lancet Neurol. 2010;9(6):581–91.
 32. Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Halbig TD, Hesekamp H, Navarro SM, Meier 
N, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368(7):610–22.
 33. De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, Morgante L, Mariani CB, Sganzerla E, Pezzoli G, Antonini A. 
Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated 
with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neuro-
surg Psychiatry. 2006;77(4):450–3.
 34. Dai H, D’Angelo LT. A portable system for quantitative assessment of parkinsonian bradykinesia during deep-brain 
stimulation surgery. In: 2013 2nd international conference on advances in biomedical engineering (ICABME), 11–13 
Sept. 2013. New York: IEEE; 2013. p. 77–80.
 35. Patel S, Hester T, Hughes R, Huggins N, Standaert D, Alice, Flaherty A, Bonato P. Using wearable sensors to enhance 
DBS parameter adjustment for Parkinson’s disease patients through measures of motor response. In: 2006 3rd IEEE/
EMBS international summer school on medical devices and biosensors, 4–6 Sept. 2006. New York: IEEE; 2006. p. 
141–4.
Page 22 of 22Machado et al. BioMed Eng OnLine  (2016) 15:169 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 36. Shah A, Coste J, Lemaire JJ, Schkommodau E, Hemm-Ode S. A method to quantitatively evaluate changes in tremor 
during deep brain stimulation surgery. In: 2013 6th international IEEE/EMBS conference on neural engineering 
(NER), 6–8 Nov. 2013. New York: IEEE; 2013. p. 1202–5.
 37. Shah A, Coste J, Schkommodau E, Lemaire JJ, Hemm-Ode S. Using acceleration sensors to quantify symptoms dur-
ing deep brain stimulation surgery. Biomed Tech. 2013;58(Suppl 1). doi:10.1515/bmt-2013-4007.
 38. Wu Z, Huang NE, Long SR, Peng C-K. On the trend, detrending, and variability of nonlinear and nonstationary time 
series. Proc Natl Acad Sci. 2007;104(38):14889–94.
 39. Andrade AO, Kyberd P, Nasuto SJ. The application of the Hilbert spectrum to the analysis of electromyographic 
signals. Inf Sci. 2008;178(9):2176–93.
 40. Andrade A. Decomposition and analysis of electromyographic signals. University of Reading. 2005.
 41. Huang NE, Shen Z, Long SR, Wu MC, Shih HH, Zheng Q, Yen N-C, Tung CC, Liu HH. The empirical mode decomposi-
tion and the Hilbert spectrum for nonlinear and non-stationary time series analysis. In: Proceedings of the Royal 
Society of London A: mathematical, physical and engineering sciences, vol 454, no. 1971. London: The Royal Society; 
1998. p. 903–95.
 42. Gruss S, Treister R, Werner P, Traue HC, Crawcour S, Andrade A, Walter S. Pain intensity recognition rates via biopoten-
tial feature patterns with support vector machines. PLoS ONE. 2015;10(10):e0140330.
 43. Sammon JW. A nonlinear mapping for data structure analysis. IEEE Trans Comput. 1969;18(5):401–9.
 44. Lerner B, Guterman H, Aladjem M, Dinsteint Ih, Romem Y. On pattern classification with Sammon’s nonlinear map-
ping an experimental study. Pattern Recogn. 1998;31(4):371–81.
 45. Mardia KV. Measures of multivariate skewness and kurtosis with applications. Biometrika. 1970;57(3):519–30.
 46. Anderson MJ. A new method for non-parametric multivariate analysis of variance. Austral Ecol. 2001;26(1):32–46.
 47. Hammer Ø, Harper DAT, Ryan PD. PAST: paleontological statistics software package for education and data analysis. 
2001.
 48. Fraley C, Raftery AE. Model-based clustering, discriminant analysis, and density estimation. J Am Stat Assoc. 
2002;97(458):611–31.
 49. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Comput-
ing; 2010.
 50. Fraley C, Raftery AE, Murphy TB, Scrucca L. Gaussian mixture modelling for model-based clustering, classification, 
and density estimation. 5.2 ed. 2016.
 51. Bronte-Stewart HM, Ding L, Alexander C, Zhou Y, Moore GP. Quantitative digitography (QDG): a sensitive measure of 
digital motor control in idiopathic Parkinson’s disease. Mov Disord. 2000;15(1):36–47.
 52. Freeman JS, Cody FW, Schady W. The influence of external timing cues upon the rhythm of voluntary movements in 
Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1993;56(10):1078–84.
 53. Nagasaki H, Itoh H, Maruyama H, Hashizume K. Characteristic difficulty in rhythmic movement with aging and its 
relation to Parkinson’s disease. Exp Aging Res. 1988;14(4):171–6.
 54. Okuno R, Yokoe M, Akazawa K, Abe K, Sakoda S. Finger taps movement acceleration measurement system for quan-
titative diagnosis of Parkinson’s disease. Conf Proc IEEE Eng Med Biol Soc. 2006;Suppl:6623–6.
 55. Shimoyama I, Hinokuma K, Ninchoji T, Uemura K. Microcomputer analysis of finger tapping as a measure of cerebel-
lar dysfunction. Neurol Med Chir. 1983;23(6):437–40.
 56. Whishaw IQ, Suchowersky O, Davis L, Sarna J, Metz GA, Pellis SM. Impairment of pronation, supination, and body co-
ordination in reach-to-grasp tasks in human Parkinson’s disease (PD) reveals homology to deficits in animal models. 
Behav Brain Res. 2002;133(2):165–76.
 57. Hellwig B, Mund P, Schelter B, Guschlbauer B, Timmer J, Lücking CH. A longitudinal study of tremor frequencies in 
Parkinson’s disease and essential tremor. Clin Neurophysiol. 2009;120(2):431–5.
